Takeda (TAK)
20.36
+0.43 (2.16%)
Upcoming Events
Latest Headlines
Takeda Entyvio trial shows disease clearance cuts UC complication risk
October 19, 2026 6:01 AM - StreetInsider
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
October 19, 2026 5:30 AM - BizWire
Takeda launches narcolepsy drug Orzeyful in Japan and China
October 15, 2026 5:58 AM - StreetInsider
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
October 14, 2026 8:30 PM - BizWire
Takeda's TAK-881 meets primary endpoint in Phase 2/3 PID trial
October 14, 2026 8:00 AM - StreetInsider
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
October 14, 2026 8:00 AM - BizWire
Takeda psoriasis drug outperforms deucravacitinib in phase 3 trial
September 30, 2026 1:02 AM - StreetInsider
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
September 30, 2026 1:01 AM - BizWire
Takeda to present phase 3 cancer drug data at ESMO 2026
September 22, 2026 9:30 AM - StreetInsider
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
September 22, 2026 9:30 AM - BizWire
Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY7,000 at Nomura/Instinet
September 18, 2026 8:56 AM - StreetInsider
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
September 18, 2026 1:01 AM - BizWire
Form 4 TAKEDA PHARMACEUTICAL For: Sep 14 Filed by: Duprey Lauren Rusckowski
September 15, 2026 9:13 PM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Sep 14
September 14, 2026 6:26 AM - SEC Filing
FDA accepts Takeda's zasocitinib drug application for plaque psoriasis
September 14, 2026 3:00 AM - StreetInsider
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
September 14, 2026 3:00 AM - BizWire
Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
September 10, 2026 8:00 AM - SEC Filing
NEJM publishes Takeda's phase 3 data on narcolepsy drug oveporexton
September 9, 2026 8:24 AM - StreetInsider
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
September 9, 2026 8:24 AM - BizWire
Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,300 at Morgan Stanley
September 4, 2026 6:59 AM - StreetInsider
Form 4 TAKEDA PHARMACEUTICAL For: Sep 02 Filed by: Plump Andrew Stewart
September 3, 2026 9:49 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
September 2, 2026 4:14 PM - SEC Filing
Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Nomura/Instinet
September 2, 2026 8:12 AM - StreetInsider
Form 6-K TAKEDA PHARMACEUTICAL For: Aug 28
August 31, 2026 6:59 AM - SEC Filing
FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera
August 28, 2026 6:40 PM - StreetInsider
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
August 28, 2026 6:40 PM - BizWire
Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY7,600 at Citi
August 25, 2026 7:11 AM - StreetInsider
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 24, 2026 2:36 AM - BizWire
Form 4 TAKEDA PHARMACEUTICAL For: Aug 19 Filed by: Plump Andrew Stewart
August 21, 2026 4:30 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 18 Filed by: Greenway Nicola Deidre Petal
August 19, 2026 4:16 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
August 19, 2026 3:59 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
August 14, 2026 4:17 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Farajallah Awny Samaan Botros
August 12, 2026 9:54 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Ibrahim Ramy Riad Ahmed
August 12, 2026 9:54 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Pacheco Rhonda Janice
August 12, 2026 9:54 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Duprey Lauren Rusckowski
August 12, 2026 9:51 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Plump Andrew Stewart
August 12, 2026 9:51 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Pignagnoli Agosti Marcello
August 12, 2026 9:47 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Bitetti Teresa Marie
August 12, 2026 9:45 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Shannon Elaine Mary
August 12, 2026 9:43 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Ricci Gabriele
August 12, 2026 9:39 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Greenway Nicola Deidre Petal
August 12, 2026 9:29 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Kim Julie So-Young
August 12, 2026 9:27 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Platford Giles Richard
August 12, 2026 9:25 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Furney Natalie Anne Marie
August 12, 2026 9:24 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Greenway Nicola Deidre Petal
August 12, 2026 4:10 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 11 Filed by: Shannon Elaine Mary
August 12, 2026 4:10 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Shannon Elaine Mary
August 10, 2026 4:31 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
August 6, 2026 5:17 PM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Aug 05
August 6, 2026 6:06 AM - SEC Filing
FDA approves Takeda's Orzeyful for narcolepsy type 1 in adults
August 5, 2026 6:10 PM - StreetInsider
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 5, 2026 6:10 PM - BizWire
Keros Therapeutics to receive $20M milestone from Takeda
July 30, 2026 4:01 PM - StreetInsider
Form 6-K TAKEDA PHARMACEUTICAL For: Jul 30
July 30, 2026 6:05 AM - SEC Filing
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
July 30, 2026 2:37 AM - BizWire
Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY5,800 at JPMorgan
July 29, 2026 8:47 AM - StreetInsider
Full Article List
